Analyst Coverage

The following analysts compile research on 4SC:

goetzpartners securities Limited

Chris Redhead, Ph.D.
The Stanley Building
7 Pancras Square
London N1C 4AG
United Kingdom

Phone: +44 (0) 20 3859 7725

31 January 2018 Flash Note 4SC AG (VSC-DE): Pivotal trial passes first safety hurdle
11 December 2017 Initiation Note 4SC AG (VSC-DE): Orphan to best-in-class: HDACi come of age

Edison Investment Research Limited

Jonas Peciulis, Ph.D.
280 High Holborn
London WC1V 7EE
United Kingdom

Phone: +44 (0) 20 3077 5734

Steady R&D newsflow

4SC | 09/02/2018

Over the past several months 4SC has reported progress with both its clinical-stage assets – resminostat and 4SC-202. The pivotal trial with resminostat…

Becoming a dermato-oncology expert

4SC | 30/10/2017

4SC’s new core strategy revealed earlier this year has focused on dermato-oncological indications, while its assets for other indications are partnered.…

Executive interview – 4SC

Executive interview – 4SC | 10/08/2017

4SC is a Munich-based cancer biopharmaceutical company. In this interview Jason Loveridge, CEO of 4SC, provides an overview of the company, its recent…

Share this page:

Follow us on: